Lv31
400 积分 2022-10-07 加入
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
1小时前
待确认
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
1小时前
已完结
Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital
6小时前
已完结
Trastuzumab rezetecan, a new antibody-drug conjugate in HER2-mutated NSCLC
1个月前
已完结
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
2个月前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
2个月前
已完结
Body Mass Index and Weight Changes in Patients with HER2-positive Early Breast Cancer: a Sub-Analysis of APHINITY trial
3个月前
已关闭
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
3个月前
已完结
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial
3个月前
已关闭
Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities
3个月前
已完结
皖公网安备34019202002308
